https://m.toutiao.com/article/7202512663753474572/?upstream_biz=toutiao_pc

Some history of Taurx n the founders

Posted by James_Bond > 1 day ago | Report Abuse
Don’t worry, casino royal fund supporting!
Those shorties will face the music! Mark my words!
Don’t you mess up with Casino Royale fund!
Personally expecting panic buying for Genting Berhad tomorrow! Cheers!
--------------------------------------------

No panic buying today leh. Tomorrow can show us Casino Royale Fund's power ok? Place 1m shares at 4.80 buy queue and another 1m shares at 4.79 buy queue, confirm can support the price and induce massive short coverings :p

Casino Royale Fund still buying? No power leh.

GenS Q3 net profit was $135m. Q4 profit dropped to $120m.

Posted by AngTayKor > 2022-10-05 11:14 | Report Abuse

Need to remember history lessons. Rm5.20 zone better becareful thats where LKT started dumping in massive volume 4 months ago.
------------------------------------------------

Posted by dompeilee > 2 days ago | Report Abuse
Hah! I already predicted last month when it was just below $5 that a sharp drop was long overdue & so I refused to chase to add even a single share to my existing holdings...it could be lim c ock tah i's family clandestinely UNLOADING like what they did last yr: release fake news about TauRx & then DUMPED 20 mil shrs to naive newbies & other funds @ 5.20...I trust no one but myself, not dragon328, not analysts, not directors who are all likely to have their own ulterior motives!
-----------------------------------------------

Looks like only one person here remembers history lessons.

For a few i3 friends that have chatted with me recently for advice and cleared promptly near 5.10 zone, congratulations.

.

Good move @ElGato. I thought its going to be a short game during their rights issue with lucidity result just around the corner. But with the active placebo fiasco, it may become another 5 yr game but hopefully not again. Im vested in Taurx since series A n i have already seen several 5 yr cycles on Taurx. I encouraged Taurx kakis to subscribe for excess rights then. Now im encouraging them to sell some when opportunity comes n take back capital first. With low entry cost price during rights n warrants we dont need to sell a lot to recover back our capital. Anything can happen in markets n investments, have to manage our own risk.

Safety always come first for me. The market will always be there to make the next investment or trade. But I have to make sure I survive (protect my capital) and doing ok (making more money than lose) in order to capitalise on the next opportunity the market offers.


To be a good trader and win real money from the stock market, you need to trade with your eyes open, recognise real trends and turns, and most importantly not wasting time with delusional wishful thinking.

.

GenS result later today

Posted by OnTime > 1 hour ago | Report Abuse
very effective made-in-china vaccines despite the constant smear campaigns by the west (singapore too!)
---------------------------------------------------

What rubbish! Singapore approves China vaccines and can be used as proof for fully vaccinated status. We have numerous clinics offering Chinese vaccines here since 2021.

Genting logo keep quiet yourself if nothing useful to contribute.

Posted by Income > 4 hours ago | Report Abuse
Bulimia or Bullish not known yet. Wait and see.
-------------------------------------------------

Fed rate up 0.25% is expected. Hawkish talk on fighting inflation by the fed is expected. Apple's earnings more market moving. I think may surprise on the downside.

Posted by emsvsi > 2 hours ago | Report Abuse
YES ENOUGH OF INCOME COMPLAINTS REMINDS ME OF SINGAPOREANS !
--------------------------------------------------

Hello don't bad mouth Singaporeans here. Genting Singapore is the one that is bringing in most of the dough for the past 2 years. If you want to see this stock above rm10, the only hope is not from Tiong tourists but from Singapore based Taurx Pharmaceuticals.

https://endpts.com/celularity-warns-of-looming-layoffs-spotlights-early-programs-as-money-runs-dry/

Alzheimer's lobbying groups can play a huge part in FDA's approval process like what we have seen during Aduhelm's approval. However such connections with the so-called non-profit Alzheimer's lobbying groups need a lot of money plus they are all already being bought over by rival amyloid drug makers.

@Riaz, FDA is a corrupted agency n personally i think CA may not be so easy without the backing of a big pharma. We are doing this regulatory process alone because at this stage if we are to cut a deal with a big pharma, it is likely to be a bad deal for us, something like 50% revenue sharing. I think our CMO Richard from Eversana is skillful in dealing FDA (but not for EMA). We are hoping for a UK CA later this year to lead in the rest of eurozone n EMA.

Recent news articles reporting HMTM treatment cost of usd2k yearly is misleading. The usd2k is suppose to be the OOP (out-of-pocket) payment by the patient for USA market, assuming a 80% medicare insurance co-pay of HMTM's usd10k yearly treatment cost.

@ElGato yes i heard abt this last Nov before Taurx AGM. On December's AGM, the sandy kingdom's flag was put on the slides. Small domestic market but there is medical tourism from other rich sandy neighbours hence a good start for HMTM!

HMTM target drug treatment cost usd10k per year. Lecanemab is usd26k per year but comes with very low drug efficacy plus brain bleeding.

https://www.statnews.com/2023/01/19/fda-rejects-lillys-bid-for-accelerated-approval-for-its-alzheimers-drug/

https://www.youtube.com/watch?v=EXIWlRrkjKE


Tiesto power. RWLV better power also!

Walau Ah Tiongs coming here to spread covid... see them better stay clear...

1.5yrs ago lecanemab applied for AA. Their final approval decision schedule at end 2023.

CMS wont cover lecanemab under AA accelerated approval

https://www.google.com/amp/s/amp.cnn.com/cnn/2023/01/06/health/lecanemab-fda-approval/index.html

Posted by Michael_chan2022 > 1 hour ago | Report Abuse

The Board wishes to announce that GENM’s indirect wholly-owned subsidiary, Genting ER II LLC, a Delaware company, had on 5 December 2022 (United States Eastern date/time) entered into a Share Purchase Agreement with Kien Huat Realty III Limited to purchase the entire 1,510 Series F Convertible Preferred Stock of Empire (“Series F”) for a total consideration of USD100 million (or RM438.5 million) (“Proposed Series F Acquisition”).
----------------------------------------------------------------

Walau another huge RPT.... LKT ah LKT....

https://www.youtube.com/watch?v=90RLzVUuXe4

Best track for 2022.

Welcome 2023. Genting comrades Huat Ah!!!

LKT is a businessman, not a stock operator or fund manager window dresser la

If Q4 net profit is very strong, we may see a small overall net profit for year 2022. As usual, LKT will declare high dividend by utilising previous decades' profit reserves. LKT is in personal financial distress n needs the high dividend more desperately than us :p

<< Approved for a broader population>>
The FDA also approved the drug for “people with Alzheimer’s disease,” a far broader population than was studied in Biogen’s clinical trials.

The investigation found that Biogen planned an aggressive marketing campaign to launch the drug, intending to spend more than $3.3 billion on sales and marketing between 2020 and 2024 – more than 2½ times what it spent to develop Aduhelm.
------------------------------------

USD3.3B budget for sales and marketing??? Seems more likely sales commission kickbacks to doctors who dare to prescribe ineffective and dangerous Aduhelm to their patients.

I think Biogen/Eisai already spent close to US$100m on PR of Lecanemab hence all the positive headline news around the world. Unfortunately Taurx does not have that kind of money and budget to burn on PR, lobbying groups and key-opinion-leaders, etc. We only have the science and safety profile to back us. Phase 3 MCI 16mg patients at 18 mths can totally halt decline plus REVERSAL is what the world needs now to stop AD pandemic.

https://edition.cnn.com/2022/12/29/health/biogen-aduhelm-alzheimers-drug-investigation/index.html

Corrupted FDA!

2023 for securing regulatory approvals worldwide. We are aiming to launch HMTM in 2024

Lets have a hypothetical example of what is the meaning of a 27% slowdown. 27% slowdown in decline means if the base score for mci patients at start of trial is 20, placebo group/ADNI score at 18mth drop to 18. Lecanemab patients drop to abt 18.5. Thats approximately 27% slowdown in decline out of the 2 point drop.

HMTM mci patients totally halt the decline plus improve score by 21% from baseline start. HMTM patients score is 24. A 20% improvement from 20 points. This is a reversal of disease progression, to real improvement. This drug not only totally halts AD progression in decline, to an improvement. It is a cure for AD!

http://www.pharmabiz.com/NewsDetails.aspx?aid=155344&sid=2


Eisai did trial for mci patients. Now applying for both mci n mild group of patients. The targeted patient market increased dramatically. If they did trial on mild patients, the trial will not see statistical significance because the expected slowdown will be by abt half of what we saw for mci patients 27% . Very cunning playing around the grey area of patient group. Regulators n CMS insurance shd be very firm just limit lecanemab to mci patients since their trial is on mci patients only.

@neohts, we already saw the phase 3 results. At 18 mths, HMTM's MCI patient group saw complete reversal of cognition decline plus improvement of 21% compared to start of trial with zero side effects. Compare this to lecanemab’s 27% slowdown with 21% patients experiencing potentially fatal side effects.

We spent a lot of time trying out 39 different blue compounds try to get a palatable drug with blue pee effect but all failed. Hence bopian went to use super low dose MTC formula of methylene blue.

GM no shares in Taurx

UK n UAE easier to score. Then use them as reference point to score for FDA n EMA but all will move concurrently in year 2023. HMTM is exactly what world need to halt AD pandemic. Cheap oral drug with zero side effects that can reverse or halt AD progression. You saw the power of HMTM. 16mg at 18mth still can see reversal for mci patients. Wtf is lecanemab’s 27% slowdown that comes with multiple death cases??? Lecanemab is rubbish.

Aiyo amateur @DreamMakers what do you know abt the AD field? Have you heard of CMA? Do you even know that Biogen's Aduhelm (F.K.A Aducanumab) did not even finish their clinical trials but was approved by FDA?

Just attended Taurx AGM webcast couple of days ago. Full focus on securing regulatory approvals for 2023. 2024 IPO valuation largely depends on how many countries' approvals Taurx can obtain. For Mild Cognitive Impairment patients at 18 month duration, Lecanemab slows down cognition by only 27% but HMTM can fully reverse cognition decline and improve by 21%. 27% vs 121%. Early AD can be cured by HMTM with zero side effects.

There is only one aunty here best friend with @DreamMakers kekeke :p

https://www.statnews.com/2022/12/22/eisai-and-biogens-latest-alzheimers-drug-needs-to-be-cheaper-than-the-last-one-analysts-say/

https://pharmaphorum.com/news/icer-says-lecanemab-data-in-alzheimers-inconclusive/

https://endpts.com/icer-on-alzheimers-lecanemab-should-be-priced-lower-than-aduhelm/

ICER on Alzheimer's: lecanemab should be priced lower than Aduhelm.

https://finance.yahoo.com/m/14b25eaa-f7e2-32bf-aab0-41e07e1d9593/billionaire-david-tepper-is.html

Big whale David Tepper Is Betting Against the Stock Market.

https://www.science.org/content/article/scientists-tie-third-clinical-trial-death-experimental-alzheimer-s-drug

Wa.... clinical trial stage only but so many patients died liow. Taurx is the only real deal ;p

Choysun lai liow! Welcome back :p

https://www.statnews.com/2022/11/28/anti-amyloid-drugs-treatment-associated-brain-shrinkage/

Thambisetty is a current FDA Adcom panel member while David Knopman resigned as FDA Adcom panel member in protest due to FDA's Aduhelm accelerated approval fiasco.

I think some amyloid drugs are so harsh at clearing away amyloid plaques that somehow it even manage to clear away a little tau tangles. Hence can see some cognition slowdown but this is largely due to a small reduction in tau tangles. Eli lily keep touting their donanemab clears amyloid deposits faster n can even clear away some Tau tangles.

@DestinyL, rate of brain atrophy is one of the endpoint measurement in lucidity trial. This is the purest form of biomarker in a clinical trial compared to reduction of amyloid deposits. Patients taking HMTM can see slower rate of brain atrophy.

Lecanemab causes brain to shrink even faster!
-------------------------


Lecanemab and other drugs that remove amyloid have another side effect that is more mysterious: They seem to cause the brain to shrink.

That concerns scientists including Thambisetty.

"Brain shrinkage represents disease progression," he says. "What is a little worrying to me is that these drugs might be worsening the degenerative process."

Alzheimer's itself causes the brain to shrink, a sign that neurons are dying. So Thambisetty expected Alzheimer's drugs to limit shrinkage, rather than accelerate it.

So did Dr. David Knopman of the Mayo Clinic. "It's moving in the wrong direction," he said during a panel at the Alzheimer's meeting.

Thambisetty wants Eisai to publish detailed information about the changes in brain volume that occurred during its study of lecanemab.